{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:41:33Z","timestamp":1770975693618,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"9240","license":[{"start":{"date-parts":[[2000,10,1]],"date-time":"2000-10-01T00:00:00Z","timestamp":970358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2000,10]]},"DOI":"10.1016\/s0140-6736(00)02871-3","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T20:46:08Z","timestamp":1027629968000},"page":"1475-1479","source":"Crossref","is-referenced-by-count":109,"title":["Mechanisms in failure of infliximab for Crohn's disease"],"prefix":"10.1016","volume":"356","author":[{"given":"Susanna","family":"Nikolaus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Raedler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"K\u00fchbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolaos","family":"Sfikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich R","family":"F\u00f6lsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(00)02871-3_bib1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3109\/00365529509096316","article-title":"Disease activity courses in a regional cohort of Crohn's disease patients","volume":"30","author":"Munkholm","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/S0140-6736(00)02871-3_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn's disease: a placebo controlled dose-ranging study","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gut.35.3.360","article-title":"Frequency of glucocorticoid resistance and dependency in Crohn's disease","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(00)02871-3_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn's disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(00)02871-3_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/BF01300378","article-title":"Tumor necrosis factor a, interleukin-1\u00df and interleukin 6 expression in inflammatory bowel disease","volume":"37","author":"Stevens","year":"1992","journal-title":"Dig Dis Sci"},{"key":"10.1016\/S0140-6736(00)02871-3_bib8","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0016-5085(92)91182-4","article-title":"Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification","volume":"103","author":"Isaacs","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.1993.tb05997.x","article-title":"Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease","volume":"94","author":"Reinecker","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/S0140-6736(00)02871-3_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(98)03339-X","article-title":"Tumor necrosis factor-a and interleukin 1\u00df in relapse of Crohn's disease","volume":"353","author":"Schreiber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(00)02871-3_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1084\/jem.171.1.35","article-title":"Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor a gene in primary macrophages","volume":"171","author":"Shakhov","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/S0140-6736(00)02871-3_bib12","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/MCB.13.10.6137","article-title":"NF-kappa B subunit specific regulation in the interleukin-8 promoter","volume":"13","author":"Kunsch","year":"1993","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0140-6736(00)02871-3_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(89)90833-7","article-title":"NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control","volume":"58","author":"Lenardo","year":"1989","journal-title":"Cell"},{"key":"10.1016\/S0140-6736(00)02871-3_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.immunol.14.1.649","article-title":"The NF-KB and I-KB proteins: new discoveries and insights","volume":"14","author":"Baldwin","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S0140-6736(00)02871-3_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(00)02871-3_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short term study of chimeric monoclonal antibody cA2 tumor necrosis factor-a for Crohn's disease","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(00)02871-3_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/gut.40.4.470","article-title":"Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve steroid dependent chronic active Crohn's disease in a pilot study","volume":"40","author":"Bauditz","year":"1997","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(00)02871-3_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Shampaio","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/S0140-6736(00)02871-3_bib21","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib22","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-a monoclonal antibody, cA2, binds recombinant transmembrane TNF-a and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/S0140-6736(00)02871-3_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/Cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"Cell"},{"key":"10.1016\/S0140-6736(00)02871-3_bib25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn's disease activity index. National Cooperative Crohn's disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib26","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0016-5085(79)90384-6","article-title":"Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)","volume":"77","author":"Best","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0016-5085(95)90004-7","article-title":"Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease","volume":"108","author":"Schreiber","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib28","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1073\/pnas.86.7.2336","article-title":"Tumor necrosis factor and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kB","volume":"86","author":"Osborn","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(00)02871-3_bib29","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1126\/science.8085155","article-title":"An interleukin-4 induced transcription factor: IL-4 Stat","volume":"265","author":"Hou","year":"1994","journal-title":"Science"},{"key":"10.1016\/S0140-6736(00)02871-3_bib30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/gut.42.4.477","article-title":"Activation of nuclear factor kB in inflammatory bowel disease","volume":"42","author":"Schreiber","year":"1998","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(00)02871-3_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stools as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(00)02871-3_bib32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0016-5085(98)70202-1","article-title":"Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa","volume":"115","author":"Rogler","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.270.5234.283","article-title":"Role of transcriptional activation by IkB in mediation of immunosuppression by glucocorticoids","volume":"270","author":"Scheinman","year":"1995","journal-title":"Science"},{"key":"10.1016\/S0140-6736(00)02871-3_bib34","first-page":"71","article-title":"Immunopharmacology of 5-aminosalicylic acid and glucocorticoids in the therapy of inflammatory bowel disease","volume":"47","author":"Nikolaus","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib35","doi-asserted-by":"crossref","unstructured":"Schreiber S, Fedorak RN, Nielsen OH, et al. Recombinant human interleukin-10 for the treatment of chronic active Crohn's diease. Gastroenterology 2000 (in press).","DOI":"10.1053\/gast.2000.20196"},{"key":"10.1016\/S0140-6736(00)02871-3_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0016-5085(99)70182-4","article-title":"Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes","volume":"116","author":"Kaiser","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib37","doi-asserted-by":"crossref","first-page":"26448","DOI":"10.1074\/jbc.274.37.26448","article-title":"Inhibition of interleukin-1-stimulated NF-kB RelA\/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity","volume":"274","author":"Egan","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/S0140-6736(00)02871-3_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib39","doi-asserted-by":"crossref","first-page":"A664","DOI":"10.1016\/S0016-5085(00)84792-7","article-title":"Infliximab exerts anti-inflammatory capacity in IBD by induction of apoptosis in monocytes","volume":"188","author":"Schmidt","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/S0140-6736(00)02871-3_bib40","doi-asserted-by":"crossref","first-page":"A335","DOI":"10.1016\/S0016-5085(00)83435-6","article-title":"Evaluation of TNF microsatellites and SNPs in a cohort of chronic active, therapy refractory Crohn's disease patients treated with anti TNF-alpha","volume":"188","author":"Mascheretti","year":"2000","journal-title":"Gastroenterology"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673600028713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673600028713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:15:20Z","timestamp":1579220120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673600028713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":40,"journal-issue":{"issue":"9240","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["S0140673600028713"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(00)02871-3","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2000,10]]}}}